info@biomedres.us
+1 (502) 904-2126
One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA
Site Map
ISSN: 2574 -1241
ISSN: 2574 -1241
Received: June 15, 2018; Published: July 20, 2018
DOI: 10.26717/BJSTR.2018.07.001452
Patients treated with anti-TNF-α agents are at increased risk of reactivating latent tuberculosis infection. Screening for tuberculosis infection and disease, and appropriate treatment before commencing of anti-TNF therapy is therefore important. However, currently recommended screening tools (tuberculin skin test, interferon-gamma releasing assays, and chest radiograph) may not detect tuberculosis infection in all children. This may result in development of active tuberculosis during TNF-α inhibitor therapy.
Keywords: Anti-TNF-α agents; Tuberculosis; Juvenile Idiopathic Arthritis; Children
Abbreviations: TNF-α: Tumor Necrosis Factor Alpha; TB: Tuberculosis; Mbt: Mycobacterium Tuberculosis; JIA: Juvenile Idiopathic Arthritis; LTBI: Latent Tuberculosis Infection; TST: Tuberculin Skin Test; IGRAs: Interferon-Gamma Releasing Assays; CXR: Chest Radiograph; CT: Computed Tomography
Abstract | Introduction | Case Report | Discussion | Conclusion | References |
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China
Department of Pharmaceutical Chemistry, Faculty of Life Sciences,, University of Vienna, Austria
Full Text
PDF
